Daily global market intelligence · Monday edition

Aman's Global Market Intelligence — 2026-08-17

Generated 08:30 CEST (Europe/Rome) · data cutoff 08:20 CEST / 06:20 UTC. U.S. cash closes are Friday 14 Aug; futures and commodities are live indications; Asian readings are near-close/live. At 08:30 Italy, Europe had not opened and many U.S. releases were still hours away.

REGIME: NEUTRAL / SELECTIVE RISK-ONOil & rates remain the vetoPaper tracking · initial two weeks

1 · Executive dashboard

S&P 500 · Fri close7,785.76−0.17%
Nasdaq Composite26,729.16−0.28%
Dow53,732.41−0.20%
Russell 20003,068.42+0.51%
VIX · Fri close14.25−2.60% vol
U.S. 2Y / 10Y4.154% / 4.680%Reuters 06:20 UTC
Dollar index99.49−0.18%
WTI / Brent$81.73 / $88.29−0.81% / −0.26%
Gold futures$4,451.70+1.63%
S&P / Nasdaq fut.+0.15% / +0.44%modestly positive
Region / indexLevelMoveSession note
Japan · Nikkei 22569,134.57+0.61%Near close, 06:15 UTC
Hong Kong · Hang Seng25,560.59+1.77%Live, not final
China · Shanghai Composite3,974.61+1.21%Live, not final
Euro Stoxx 506,539.59−0.09%Friday close; futures +0.3% pre-open
Germany · DAX26,440.31+0.53%Friday close
UK · FTSE 10010,750.10−0.21%Friday close

Three key developments

  1. Rate-hike odds retreat: soft retail sales and sentiment pushed September hike pricing to 30% from ~50% one week ago; the dollar and front-end yields eased. Reuters
  2. Asia / futures lean positive: Chinese shares led and Nasdaq futures outperformed, but this is not broad confirmation before cash trading.
  3. Hormuz risk persists: Brent remained near $88 after a 6% weekly rise. High oil can reverse the benign rates impulse through inflation and margins.

Regime logic

Neutral / selective risk-on

Lower dollar, softer short yields, VIX below 15 and green Nasdaq futures help duration assets. Counterweight: 10Y near 4.68%, Brent above $88 and unresolved Gulf supply risk. Prefer confirmed relative strength; do not extrapolate a thin pre-open.

2 · Market drivers

Macro & central banks

  • Monday 08:30 ET Empire State manufacturing (consensus 12; prior 15.6) and 10:00 ET NAHB (33; prior 34). These occur after publication. Calendar
  • Wednesday's July FOMC minutes are the policy gate; the official Fed calendar confirms the July 28–29 meeting and September 15–16 next decision. Federal Reserve
  • Tuesday import/export prices are the week's next official BLS inflation input. BLS

Rates, FX & commodities

  • 2Y 4.154% and 10Y 4.680% imply a positively sloped 52.6 bp curve; softer front-end pricing helps growth, while the high long end still constrains valuations.
  • EUR/USD touched $1.1588, a two-month high; weaker dollar supports gold and non-U.S. risk but can reflect softer U.S. data.
  • Oil is the principal cross-asset shock channel. A sustained WTI move above $85 would challenge the selective risk-on label.

Earnings, rotation & unusual moves

  • Friday breadth rotated toward small caps: Russell +0.51% while Nasdaq −0.28%.
  • Broadcom fell 5.94% to $392.99 on Friday. Secondary reports tied the move partly to an actively exploited VMware vulnerability; lacking a captured Broadcom/CISA primary notice here, treat causality as not fully verified. Price/volume weakness itself is verified by Yahoo data.
  • Consumer read-throughs this week include Home Depot, Target and Walmart, per Reuters; recheck each IR page before trading exact times.

Geopolitics & regulation

  • Iran/Hormuz stalemate and reduced Middle East flows remain the highest-impact overnight risk. Reuters cited an estimated 10–15% shortfall versus normal flows in a strategist scenario—not a confirmed physical-flow statistic.
  • Semiconductor export controls, cloud customer concentration and AI financing remain structural risks even without a new primary rule this morning.

3 · Theme dashboards

AI / semiconductors / infrastructure

Leader: VRT Gate: NVDA Laggard: AVGO Friday

  • NVDA $225.16, −0.06% Friday: Q2 FY27 results are officially scheduled Aug. 26 at 14:00 PT. Q1 revenue was $81.6B and data center $75.2B, +85% and +92% y/y respectively. NVIDIA IR event · Q1 release
  • VRT $293.84, +2.36%: verified relative strength, but no new primary catalyst captured this morning; high AI-capex beta makes confirmation mandatory.
  • AVGO $392.99, −5.94%: do not catch the first bounce without a base. The long-term AI/custom-silicon thesis can coexist with near-term software/security and valuation risk.

Valuation/speculation risk: record index levels plus a 4.68% 10Y leave little tolerance for guidance misses. Earnings-gap risk dominates precise technical stops.

Quantum computing

Speculative only

  • Friday: IONQ $46.26 (+2.85%), RGTI $18.82 (+1.07%), QBTS $21.17 (+1.29%).
  • No fresh, independently verified primary milestone was found this morning. Price strength is not technical/commercial validation.
  • Pure plays remain pre-profit, acquisition/dilution-sensitive and vulnerable to contract timing. Prefer milestone verification (fidelity, error correction, useful workload, cash use) over qubit headlines.

Leaders/laggards: IONQ led Friday's trio; none qualifies as a low-risk core holding. IonQ's dynamic IR filing table did not expose filing rows to extraction; SEC/company filing verification remains required before sizing.

Peptide-drug biotechnology

Commercial leader: LLY Binary small-cap: VKTX

  • LLY $1,180.16, −2.39% Friday: Q2 revenue $22.974B (+48% y/y), Mounjaro $9.943B (+91%) and Zepbound $4.928B (+46%); 2026 revenue guidance rose to $85–87B. Lilly Q2 primary release
  • Retatrutide Phase 3 obesity data showed −19.0%, −25.9% and −28.3% average weight change at week 80 for 4/9/12 mg versus −2.2% placebo. AE discontinuations were 4.1%, 6.9%, 11.3% versus 4.9%; GI events and dysesthesia require scrutiny. Primary release
  • TRIUMPH-3 (NCT05882045) was randomized, double-blind Phase 3, actual n=1,946, completed May 14, with week-80 body-weight primary endpoint; the registry does not yet supply results in the captured record. ClinicalTrials.gov

Risks: valuation, reimbursement, manufacturing, GI/tolerability, regulatory labeling, competition and readout-to-approval translation. Small-cap VKTX adds binary efficacy/safety and dilution exposure.

4 · Ranked ideas · conditional paper setups

Fewer is better. No unconditional short is compelling this morning; bearish entries are classified avoid / wait, not borrow claims.

#1 NVDA · NVIDIA Conditional bullish

Nasdaq · mega-cap · AI compute/networking · premium earnings-gap risk

Day: applicable after breadth1–4 weeks: applicable, event-sized3–12+ months: staggered

Direction / thesis / catalyst: uncertain positive. Friday held near the prior $224 breakout area; Aug. 26 earnings are the decisive catalyst. Record Q1 data-center growth is primary evidence.

Evidence / counterargument: $81.6B Q1 revenue and $75.2B data-center revenue demonstrate momentum. Counter: extraordinary expectations, export controls, customer concentration, power/HBM constraints and custom accelerators can compress the multiple even on growth.

Entry / confirmation: paper entry only if $224 holds after the first hour and semis/data-center peers participate; alternative is a controlled $220–224 reclaim. Invalidation/downside: daily close below $216, broad AI breakdown, adverse export rule or material order/guidance miss. A results gap can bypass stops.

Key risks: Aug. 26 gap, valuation, supply/power, competition, export policy and customer financing.

Confidence
84
Risk
79
Opportunity
72

#2 VRT · Vertiv Momentum bullish

NYSE · large-cap · power/cooling · high AI-capex beta

Day: conditional1–4 weeks: applicable3–12+ months: applicable, staggered

Direction / thesis / catalyst: uncertain positive. Friday +2.36% relative strength supports the data-center power/cooling bottleneck thesis; NVDA results provide a sector catalyst.

Evidence / counterargument: price held momentum while the Nasdaq declined. Counter: no new primary company catalyst was captured today, and a crowded AI-capex trade can reverse sharply on rates or hyperscaler-spend doubts.

Entry / confirmation: hold $287 on a pullback or volume-backed break above Friday's range; require market breadth. Invalidation/downside: close below $280 or sustained underperformance versus the Nasdaq; gap risk remains.

Key risks: valuation, project timing, customer concentration, supply chain, oil/yields and crowded positioning.

Confidence
73
Risk
83
Opportunity
66

#3 AVGO · Broadcom Avoid first bounce

Nasdaq · mega-cap semiconductor/software · not a short recommendation

Day: avoid early knife-catch1–4 weeks: wait for base3–12+ months: watch execution

Direction / thesis / catalyst: uncertain bearish/avoid after Friday's −5.94% abnormal loss. The immediate burden is stabilization and clarity around the VMware security report.

Evidence / counterargument: the price break is verified; secondary sources report active exploitation of a vCenter flaw. Counter: attribution is not primary-source cross-checked here, and Broadcom retains AI custom-silicon/networking exposure, so a squeeze/reversal is plausible.

Entry / confirmation: no bearish entry and no borrow claim. Upgrade only after a multi-session base and reclaim of Friday breakdown levels with news clarity. Invalidation/downside: avoid thesis invalidates on durable reclaim/relative strength; downside risk worsens on a fresh high-volume low.

Key risks: security remediation, software reputation, AI expectations, valuation and violent rebound.

Confidence
68
Risk
88
Opportunity
39

#4 IONQ · IonQ Avoid chase

NYSE · speculative pre-profit quantum · extreme volatility / dilution risk

Day: specialists only1–4 weeks: catalyst-sized only3–12+ months: venture-sized

Direction / thesis / catalyst: uncertain bearish/avoid-chase after +2.85% Friday without a fresh verified technical or commercial milestone this morning.

Evidence / counterargument: sector prices rose, but price is not proof of useful quantum advantage. Counter: contract announcements or roadmap evidence can trigger a squeeze.

Entry / confirmation: require a stable base plus independently verifiable fidelity/error-correction, bookings-to-revenue and cash-use milestones. Invalidation/downside: avoid stance changes on those milestones; downside worsens on a failed breakout/new base low.

Key risks: dilution, stock compensation, acquisitions/integration, technical slippage, lumpy contracts and extreme sentiment. No borrow availability or fee representation.

Confidence
76
Risk
96
Opportunity
40

Watchlist · maximum five

Ticker / classClassification & horizonConfirmation / invalidationC / R / O
GOOGL · Nasdaq mega-capQuality watch; day/swing/long. Cloud/AI cash generation versus antitrust, capex and AI-search disruption.Confirm relative-strength breakout; invalidate on catalyst-gap rejection and sustained benchmark underperformance.87 / 61 / 65
LLY · NYSE mega-cap peptideCommercial leader; swing/long, not a day setup. Fundamentals strong; technical repair needed.Reclaim $1,200 then $1,220; invalidate on new closing low plus estimate cuts or material safety/access deterioration.88 / 72 / 60
VKTX · Nasdaq small-cap biotechBinary catalyst watch; swing/venture only. Phase 3 and maintenance-data exposure.Require protocol, estimand, statistics, completion/dropout and safety. Invalidate on weak durability, delay, safety imbalance or runway erosion.79 / 97 / 57
RGTI · Nasdaq speculative quantumMilestone watch only; day specialists / venture-sized long.Require verified technical performance and commercial conversion; invalidate on roadmap slip or financing deterioration.64 / 97 / 38
CBRS · Nasdaq newly public AIAvoid until base; all horizons high risk. Limited public history and price discovery.Require multi-session stability, revenue quality and repeatable margin evidence; invalidate watch on continued high-volume lows.72 / 96 / 30

5 · Changes versus the 2026-08-16 report

ItemPreviousTodayAction
RegimeNeutral / selective risk-on; await futuresNasdaq futures +0.44%, Asia positive, dollar softer; oil still elevatedRegime retained, now with modest live confirmation—not enough for open-chasing
NVDA#1 conditional bullish$225.16 Friday; official Aug. 26 earnings confirmedRetain #1; confirmation still $224 plus breadth
VRTWatchlistFriday +2.36% relative strengthPromote to #2 conditional bullish; risk remains high
AVGONot rankedFriday −5.94%; VMware vulnerability attribution only secondarily sourcedAdd avoid-first-bounce; no short claim
CBRS / CRWVAvoidNo new verified primary repairCBRS remains watch/avoid; CRWV removed to keep list focused
Quantum / peptidesIONQ, VKTX watch; LLY repairNo new quantum milestone; Lilly fundamentals primary-verifiedIONQ avoid-chase; LLY/VKTX remain watchlist

6 · Important 7–30 day catalysts

Mon Aug. 17 · 08:30 / 10:00 ET
Empire State manufacturing / NAHB. Today's 08:30 Italy publication precedes both.
Tue Aug. 18
BLS import/export prices at 08:30 ET; housing, industrial production and capacity utilization add growth/rates signals. Verify release agencies before execution.
Aug. 18–20
Home Depot, Target and Walmart consumer read-throughs; exact earnings times require company-IR recheck.
Wed Aug. 19 · 14:00 ET
July FOMC minutes: inflation-risk debate and reaction function.
Fri Aug. 21 · 09:45 ET
Flash U.S. manufacturing/services PMI, the week's principal business-activity check.
Wed Aug. 26 · 14:00 PT
NVIDIA Q2 FY27 results; largest AI-sector valuation and guidance gate. Same day U.S. GDP/PCE/durables data raise cross-asset gap risk.
Q3 2026
Viking VK2735 maintenance-dosing data: require statistical methods, estimand, dropout, adverse events and durability—not a headline percentage.
Tue Sep. 8
IonQ Investor Day (from prior primary calendar verification): require specific roadmap, revenue-conversion and cash-use milestones; reverify event.
Sep. 15–16
FOMC meeting, confirmed by the Federal Reserve; oil/inflation path determines whether cuts/hikes or hold dominate.

7 · Bottom line by horizon

Day trade

Wait for the first-hour U.S. cash tape. Preferred paper setup: NVDA holds $224 while semis and VRT participate. Do not buy AVGO's first bounce or chase quantum. Biggest intraday veto: WTI and 10Y rising together.

1–4 week swing

NVDA is the primary conditional long but must be event-sized for Aug. 26. VRT needs $287 support/relative strength. LLY needs a $1,200 reclaim. Avoid adding binary quantum/biotech exposure without specific milestone data.

3–12+ month investment

Favor cash-generative AI platforms/infrastructure and scaled peptide commercialization over newly public price discovery or pre-profit quantum. Stagger entries: 4.68% long yields and $88 Brent can compress quality multiples.

Biggest risk: Hormuz disruption keeps Brent/WTI elevated, revives inflation and lifts long yields while softer U.S. demand slows earnings. Risk-on validation: WTI <$80, 10Y <4.60%, VIX <15 and broad participation. Regime invalidation: 10Y >4.80%, WTI >$85, VIX >17 or S&P breakout failure with worsening breadth.

8 · Sources & data quality

Data-quality panel
  • Timestamp generated live with TZ=Europe/Rome date: 2026-08-17 08:30 CEST.
  • Prices: Yahoo Finance chart API retrieved 06:20 UTC; U.S./European cash readings are Aug. 14 closes, futures/FX/commodities are Aug. 17 indications. Reuters cross-check at approximately 06:20 UTC gave S&P futures +0.1%, Nasdaq futures +0.3%, 2Y 4.154%, 10Y 4.680%, Brent $88.67 and gold $4,391. Small differences reflect instrument (cash/spot/future) and timestamp.
  • Primary retrievals used NVIDIA IR, Lilly IR, ClinicalTrials.gov API, BLS and Federal Reserve. Current news was cross-checked with Reuters.
  • Limitations / retries: MarketWatch's linked futures article returned 404 (Reuters and Yahoo substituted); Lilly's generic news-releases URL returned “Page Not Found” (specific primary Q2/retatrutide releases substituted); Rigetti's guessed SEC-filings path returned 404 (no current Rigetti filing fact asserted); IonQ's dynamic IR table loaded without rows (no filing-derived numeric claim asserted). Broadcom vulnerability causality remains secondary-only and is labeled accordingly.
  • Scores are structured research judgments, not probabilities. Confidence measures evidence quality, not guaranteed success.
  1. Reuters — Asian shares rise, dollar slips as markets pare Fed rate risks
  2. Yahoo Finance chart API example — S&P 500
  3. NVIDIA IR — events · financial reports
  4. Lilly Q2 2026 primary release · retatrutide Phase 3 primary release
  5. ClinicalTrials.gov — TRIUMPH-3
  6. BLS August calendar · Federal Reserve FOMC calendar · MarketWatch economic calendar
  7. TipRanks secondary report on AVGO/VMware — used cautiously, not treated as primary confirmation.